IPP Bureau
CARsgen and Dispatch Bio launch groundbreaking CAR T collaboration in China
By IPP Bureau - January 15, 2026
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
By IPP Bureau - January 15, 2026
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
BD announces $110 million investment in Nebraska to expand prefillable syringe production
By IPP Bureau - January 15, 2026
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids
By IPP Bureau - January 15, 2026
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
FDA endorses Relmada’s registrational strategy for bladder cancer therapy
By IPP Bureau - January 14, 2026
Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
By IPP Bureau - January 14, 2026
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
ISVIR 2026 showcases cutting-edge interventional radiology in India
By IPP Bureau - January 14, 2026
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Merck scores FDA nod for TGT drug Pimicotinib, promising new hope for patients
By IPP Bureau - January 14, 2026
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Codexis teams up with Axolabs to advance enzymatic RNA manufacturing
By IPP Bureau - January 14, 2026
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
Avista Therapeutics unveils AI-powered expansion of gene therapy platform
By IPP Bureau - January 14, 2026
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Camurus’ Oclaiz NDA resubmission accepted by FDA
By IPP Bureau - January 14, 2026
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery
By IPP Bureau - January 14, 2026
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
By IPP Bureau - January 14, 2026
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
By IPP Bureau - January 14, 2026
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
FDA nod to first-ever treatment for fatal pediatric Menkes disease
By IPP Bureau - January 14, 2026
